Acitretin systemic and retinoic acid 0.1% cream supression of basal cell carcinoma.
Dermatol Reports
; 2(1): e4, 2010 Jan 18.
Article
en En
| MEDLINE
| ID: mdl-25386240
Retinoids have been used for years as monotherapy and/or in combination for treatment and suppression of cutaneous malignancies in patients with basal cell nevus syndrome, xeroderma pigmentosum, or cutaneous T-cell lymphoma (CTCL) basal cell carcinoma (BCC). We report 4 cases with BCC confirmed by histopathology who were treated by short-term systemic acitretin combined with retinoic acid 0.1% cream. The 4 cases with BCC showed good response to the treatment without severe adverse effects during treatment and follow-up. The finding suggests that acitretin may be an appropriate treatment option for elderly patients who require less invasive treatment for BCC.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Dermatol Reports
Año:
2010
Tipo del documento:
Article
Pais de publicación:
Italia